JP2018515506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515506A5 JP2018515506A5 JP2017558372A JP2017558372A JP2018515506A5 JP 2018515506 A5 JP2018515506 A5 JP 2018515506A5 JP 2017558372 A JP2017558372 A JP 2017558372A JP 2017558372 A JP2017558372 A JP 2017558372A JP 2018515506 A5 JP2018515506 A5 JP 2018515506A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- disease
- disorder
- calcium
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 206010012289 Dementia Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000008188 pellet Substances 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 229960001157 acamprosate calcium Drugs 0.000 claims 2
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 230000004641 brain development Effects 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000030251 communication disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 230000013016 learning Effects 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000015654 memory Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 238000003892 spreading Methods 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 229920001169 thermoplastic Polymers 0.000 claims 1
- 239000004416 thermosoftening plastic Substances 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103349A JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156842P | 2015-05-04 | 2015-05-04 | |
| US62/156,842 | 2015-05-04 | ||
| US201562260161P | 2015-11-25 | 2015-11-25 | |
| US62/260,161 | 2015-11-25 | ||
| PCT/US2016/030725 WO2016179252A1 (en) | 2015-05-04 | 2016-05-04 | Sprinkle formulations of acamprosate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103349A Division JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515506A JP2018515506A (ja) | 2018-06-14 |
| JP2018515506A5 true JP2018515506A5 (enExample) | 2019-06-06 |
| JP7026347B2 JP7026347B2 (ja) | 2022-02-28 |
Family
ID=57217823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558372A Active JP7026347B2 (ja) | 2015-05-04 | 2016-05-04 | アカンプロサートのスプリンクル製剤 |
| JP2021103349A Pending JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103349A Pending JP2021155434A (ja) | 2015-05-04 | 2021-06-22 | アカンプロサートのスプリンクル製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10709668B2 (enExample) |
| EP (1) | EP3291800A4 (enExample) |
| JP (2) | JP7026347B2 (enExample) |
| KR (1) | KR102790656B1 (enExample) |
| AU (1) | AU2016258624B2 (enExample) |
| HK (1) | HK1252003A1 (enExample) |
| IL (1) | IL255343B2 (enExample) |
| SG (1) | SG11201708393UA (enExample) |
| WO (1) | WO2016179252A1 (enExample) |
| ZA (1) | ZA201708037B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016132136A1 (en) | 2015-02-18 | 2016-08-25 | Aston University | Diagnostic assay and treatment for preeclampsia |
| KR102790656B1 (ko) | 2015-05-04 | 2025-04-02 | 컨플루언스 파마슈티컬스, 엘엘씨 | 아캄프로세이트의 스프링클 제형 |
| AU2016303610A1 (en) * | 2015-08-04 | 2018-02-01 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and D-cycloserine |
| EP3624788A4 (en) * | 2017-05-17 | 2021-03-03 | Confluence Pharmaceuticals, LLC | FORMULATIONS OF HOMOTAURIN AND SALT THEREOF |
| ES2938609T3 (es) * | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
| EP4213817A1 (en) * | 2020-09-21 | 2023-07-26 | Sun Pharmaceutical Industries Limited | Multi-particulate pharmaceutical composition of quetiapine |
| US20240382133A1 (en) | 2021-09-24 | 2024-11-21 | Sumitomo Bakelite Co., Ltd. | Brain wave detection electrode, brain wave measuring device, and brain wave measuring method |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514530B2 (en) | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
| AU765603C (en) | 1998-04-14 | 2004-08-05 | General Hospital Corporation, The | Methods for treating neuropsychiatric disorders |
| RU2375048C2 (ru) * | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| WO2009004082A2 (en) | 2007-07-05 | 2009-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticonvulsive pharmaceutical compositions |
| ES2530047T3 (es) | 2009-02-12 | 2015-02-26 | Indiana University Research And Technology Corporation | Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20110142889A1 (en) | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| US9000046B2 (en) * | 2010-09-28 | 2015-04-07 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
| RS53227B (sr) | 2011-03-01 | 2014-08-29 | Pharnext | Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata |
| WO2012129551A1 (en) * | 2011-03-23 | 2012-09-27 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
| WO2013002584A2 (ko) | 2011-06-28 | 2013-01-03 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| AU2012345659B2 (en) * | 2011-12-02 | 2017-09-28 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| WO2014197744A1 (en) * | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| EP3104850A1 (en) | 2014-02-11 | 2016-12-21 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| KR102790656B1 (ko) | 2015-05-04 | 2025-04-02 | 컨플루언스 파마슈티컬스, 엘엘씨 | 아캄프로세이트의 스프링클 제형 |
-
2016
- 2016-05-04 KR KR1020177033137A patent/KR102790656B1/ko active Active
- 2016-05-04 US US15/569,937 patent/US10709668B2/en active Active
- 2016-05-04 JP JP2017558372A patent/JP7026347B2/ja active Active
- 2016-05-04 IL IL255343A patent/IL255343B2/en unknown
- 2016-05-04 HK HK18111332.4A patent/HK1252003A1/zh unknown
- 2016-05-04 WO PCT/US2016/030725 patent/WO2016179252A1/en not_active Ceased
- 2016-05-04 AU AU2016258624A patent/AU2016258624B2/en active Active
- 2016-05-04 EP EP16789996.2A patent/EP3291800A4/en active Pending
- 2016-05-04 SG SG11201708393UA patent/SG11201708393UA/en unknown
-
2017
- 2017-11-27 ZA ZA2017/08037A patent/ZA201708037B/en unknown
-
2021
- 2021-06-22 JP JP2021103349A patent/JP2021155434A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255782A (en) | Extended release pharmaceutical compositions of levetiracetam | |
| Ling et al. | All-carbon quaternary centers in natural products and medicinal chemistry: recent advances | |
| JP2011063627A5 (enExample) | ||
| King et al. | Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments | |
| CA2936746C (en) | Methods and compositions particularly for treatment of attention deficit disorder | |
| JP2018516906A5 (enExample) | ||
| PH12019502782A1 (en) | Fixed dose formulations | |
| CN115521217A (zh) | 神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法 | |
| JP2017536407A5 (enExample) | ||
| SG10201803812TA (en) | Neuroactive steroids, compositions, and uses thereof | |
| FI3702351T3 (fi) | MEK-inhibiittorin käsittävä koostumus | |
| JP2016147915A5 (enExample) | ||
| NZ591873A (en) | Co-crystals of tramadol and nsaids | |
| JP2017019874A (ja) | アマンタジン組成物および使用方法 | |
| JP2014516535A5 (enExample) | ||
| JP2018526345A5 (enExample) | ||
| WO2008120070A3 (en) | 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic action, a method for its production and a pharmaceutical composition based thereon | |
| BR112013016818A2 (pt) | formulação | |
| WO2017134685A3 (en) | Novel hydrazino compounds as btk inhibitors | |
| JP2014507475A5 (enExample) | ||
| CN106265601A (zh) | 一种布洛芬缓释制剂及其制备方法 | |
| CN104940160A (zh) | 改进的磷酸奥司他韦固体组合物及其制备方法 | |
| JP2018536707A5 (enExample) | ||
| CN103816135B (zh) | 盐酸美金刚缓释制剂及其制备方法 | |
| CN101947209B (zh) | 双丙戊酸钠小丸及其制备方法 |